ESPE Abstracts (2015) 84 P-3-945

As Great Intra as Interindividual Variability in Uptake of s.c. GH Injections in Longitudinally Followed GH Treated Children

Elena Lundberga, Berit Kriströma, Björn Anderssonb, Sten Rosbergb & Kerstin Albertsson-Wiklandc

aDepartment of Pediatrics, Institute of Clinical Sciences, Umeå University, Umeå, Sweden; bDepartment of Pediatrics, Göteborg Pediatric Growth Research Center, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sweden, Göteborg, Sweden; cDepartment of Physiology/Endocrinology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden, Göteborg, Sweden

Background: The variation in uptake of daily sc GH-injections is hardly known.

Objective and hypotheses: There is a considerable variability in uptake of s.c. GH-injections both within and between children.

Method: 65 children used (Genotropin® pen 4/16, needle 12 mm), dose 0.08–0.14 mU/kg per day within trials: TRN 87–010; 88–080; 88–177; followed yearly two–eight times 1992–1999 (n=214). GHserum-sampling every 2nd h, before and until 16 h after the s.c. GHinj at 18.00 h, given by patient/parent under nurses’ supervision: 90° deep sc in femoral muscle. GH was analysed by Pharmacia Polyclonal assay, IRP 80–505, with CV 10%. Pharmacokinetic estimates were Tmax (h), Cmax (ug/l), AUC 16 h. The GH-curves divided into group A: back-to-baseline within 16 h (n=46), group B: did not return (n=70), group C: suspected GHpeak from endogenous secretion (n=74). Values given as median (coefficient of variation, CV %).

Results: Interindividual variation: group A: with Cmax 64 (45) at Tmax 4 (42), AUC1 6 h 407 (40) and back-to-baseline after 16 h (43). Group B: Cmax 61 (50), Tmax 4 (38), AUC 16 h 420 (40). Group C: Cmax 60 (56), Tmax 4 (60), AUC 16 h 431 (52). Intra-individual variation: group A+B+C: 51 subjects with 2–8 times=190 curves: Cmax 63 (36), Tmax 4 (41), AUC 16 h 426 (32).

Conclusion: As great intra and inter-individual variability in GH uptake from s.c. injection was found. The impact on growth and IGF1 response remains to be elucidated.

Funding: These investigator-initiated and sponsored studies (TRN 88-080; TRN 88-177; TRN 89-071; TRN 98-0198-003) were supported by unrestricted research grants from Pharmacia/Pfizer, the Swedish Research Council grant no 7509, the Foundation Växthuset for Children, Sahlgrenska University Hospital (ALF), West Sweden Region (VGR) grants, and the County Council of Östergötland.

Article tools

My recent searches

No recent searches.